HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Esthesioneuroblastoma (olfactory neuroblastoma) treated with 111In-octreotide and 177Lu-DOTATATE PRRT.

Abstract
A 51-year-old man with a recurrent metastatic esthesioneuroblastoma (olfactory neuroblastoma) was referred for peptide receptor radionuclide therapy (PRRT). He received 4 treatments of 111In-octreotide over 8 months and 3 treatments of 177Lu-DOTATATE over 4 months, which helped alleviate his symptoms and improved his quality of life; however, the tumor ultimately progressed and he passed away shortly thereafter. PRRT with 111In-octreotide or 177Lu-DOTATATE could play a role in the management of esthesioneuroblastoma.
AuthorsWilliam Makis, Karey McCann, Alexander J B McEwan
JournalClinical nuclear medicine (Clin Nucl Med) Vol. 40 Issue 4 Pg. 317-21 (Apr 2015) ISSN: 1536-0229 [Electronic] United States
PMID25674857 (Publication Type: Case Reports, Journal Article)
Chemical References
  • Organometallic Compounds
  • Radiopharmaceuticals
  • indium-111-octreotide
  • lutetium Lu 177 dotatate
  • Octreotide
Topics
  • Esthesioneuroblastoma, Olfactory (radiotherapy)
  • Humans
  • Male
  • Middle Aged
  • Nasal Cavity (pathology)
  • Nose Neoplasms (radiotherapy)
  • Octreotide (analogs & derivatives, therapeutic use)
  • Organometallic Compounds (therapeutic use)
  • Radiopharmaceuticals (therapeutic use)

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: